ustekinumab
Johnson & Johnson Sues Samsung Bioepis Over Alleged Stelara Biosimilar Contract Breach
Johnson & Johnson, Samsung Bioepis, Stelara, biosimilar, lawsuit, contract breach, ustekinumab, Pyzchiva
Biocon Biologics Secures FDA Approval for YESINTEK, a Biosimilar to Stelara
Biocon Biologics, FDA approval, YESINTEK, Stelara biosimilar, ustekinumab, inflammatory diseases
Lilly’s Omvoh Outperforms J&J’s Stelara in Phase III Crohn’s Disease Trial
Omvoh (mirikizumab), Stelara (ustekinumab), Crohn’s disease, Phase III trial, Inflammatory bowel disease (IBD), Eli Lilly, Johnson & Johnson
Mirikizumab Shows Superior Histologic Response in Crohn’s Disease Compared to Ustekinumab
Mirikizumab, Ustekinumab, Crohn’s Disease, Histologic Response, VIVID-1 Trial, Inflammatory Bowel Disease
FDA Tracker: Fresenius Kabi and Formycon’s Stelara Biosimilar Set for 2025 Launch
Stelara biosimilar, Fresenius Kabi, Formycon, FDA approval, ustekinumab, Johnson & Johnson, J&J settlements, biosimilar competition